ETS Transcription Factors Control Transcription of EZH2 and Epigenetic Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer
Open accessThe DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ETS transcription factors regulate important signaling pathways involved in cell differentiation and development in many tissues and have emerged as important players in prostate cancer. However, the biological impact of ETS factors in prostate tumorigenesis is still debated. METHODOLOGY/PRINCIPAL FINDINGS: We performed an analysis of the ETS gene family using microarray data and real-time PCR in normal and tumor tissues along with functional studies in normal and cancer cell lines to understand the impact in prostate tumorigenesis and identify key targets of these transcription factors. We found frequent dysregulation of ETS genes with oncogenic (i.e., ERG and ESE1) and tumor suppressor (i.e., ESE3) properties in prostate tumors compared to normal prostate. Tumor subgroups (i.e., ERG(high), ESE1(high), ESE3(low) and NoETS tumors) were identified on the basis of their ETS expression status and showed distinct transcriptional and biological features. ERG(high) and ESE3(low) tumors had the most robust gene signatures with both distinct and overlapping features. Integrating genomic data with functional studies in multiple cell lines, we demonstrated that ERG and ESE3 controlled in opposite direction transcription of the Polycomb Group protein EZH2, a key gene in development, differentiation, stem cell biology and tumorigenesis. We further demonstrated that the prostate-specific tumor suppressor gene Nkx3.1 was controlled by ERG and ESE3 both directly and through induction of EZH2. CONCLUSIONS/SIGNIFICANCE: These findings provide new insights into the role of the ETS transcriptional network in prostate tumorigenesis and uncover previously unrecognized links between aberrant expression of ETS factors, deregulation of epigenetic effectors and silencing of tumor suppressor genes. The link between aberrant ETS activity and epigenetic gene silencing may be relevant for the clinical management of prostate cancer and design of new therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to the chromosome rearrangements described above, there is mounting evidence for an oncogenic role for dysregulation of ETS genes in prostate (188, 188a), melanoma (189), and gastrointestinal stromal tumors (140).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [188]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro
Liang, C.-C., Park, A. Y., & Guan, J.-L. (2007) · Nature Protocols · doi:10.1038/nprot.2007.30 · Cited by 4,696 · cited 1×
“Cell migration was assessed using the scratch wound healing assay [47].”
MethodRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · cited 1×
“EZH2 is up-regulated in many cancers, including clinically localized and metastatic prostate cancers [19,37].”
BackgroundPolycomb complexes repress developmental regulators in murine embryonic stem cells
Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., Levine, S. S., Wernig, M., Tajonar, A., Ray, M. K., et al. (2006) · Nature · doi:10.1038/nature04733 · Cited by 2,514 · cited 1×
“EZH2 is a key factor in the execution of development and differentiation programs as well as in maintenance of pluripotency and self-renewal of stem cells [38,39].”
BackgroundInflammation in prostate carcinogenesis
De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2090 · Cited by 1,621 · cited 3×
“cause of cancer death in western countries [1].”
BackgroundEZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196 · cited 2×
“EZH2 expression in prostate tumors [20,21,22,23].”
BackgroundThe ETS-domain transcription factor family
Sharrocks, A. D. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099076 · Cited by 1,086
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Varambally, S., Cao, Q., Mani, R.-S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., et al. (2008) · Science · doi:10.1126/science.1165395 · Cited by 1,052 · cited 2×
“EZH2 expression in prostate tumors [20,21,22,23].”
BackgroundIntegrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922 · cited 2×
“This approach has been applied in previous studies [27,34].”
BackgroundResultDistinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844 · cited 1×
“recently attracted significant attention in prostate cancer since the identification of recurrent ETS gene rearrangements leading to their over-expression [2,3,4].”
BackgroundYamane, K., Toumazou, C., Tsukada, Y.-I., Erdjument-Bromage, H., Tempst, P., Wong, J., & Zhang, Y. (2006) · Cell · doi:10.1016/j.cell.2006.03.027 · Cited by 837 · cited 1×
“1 gene [30] in ERG-translocation positive VCaP cells (Fig.”
BackgroundRole of the TMPRSS2-ERG Gene Fusion in Prostate Cancer
Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., Cao, Q., Prensner, J. R., Rubin, M. A., Shah, R. B., et al. (2008) · Neoplasia · doi:10.1593/neo.07822 · Cited by 690 · cited 4×
“To validate these cellular models, we examined the expression of genes, like MMP3, PLA-1 and CRISP3, which were at the top of the list of up-regulated genes in ERG tumors and had been previously shown to be controlled by ERG in other cell systems [6].”
BackgroundMethodInfluentialRecurrent gene fusions in prostate cancer
Kumar-Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2402 · Cited by 664 · cited 2×
“Genetic events or pathological conditions, such as gene rearrangements [3] or chronic inflammation [1], could shift the equilibrium in favor of oncogenic ETS, like ERG and ESE1, and promote the activation of promitogenic, pro-survival and dedifferentiation programs.”
BackgroundAberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T., et al. (2009) · Nature Genetics · doi:10.1038/ng.370 · Cited by 659 · cited 1×
“tion and cooperation with other oncogenic pathways, such as PTEN loss and PI3K/AKT dysregulation, is necessary [5,6,7,8,9].”
BackgroundKondo, Y., Shen, L., Cheng, A. S., Ahmed, S., Boumber, Y., Charo, C., Yamochi, T., Urano, T., Furukawa, K., Kwabi-Addo, B., et al. (2008) · Nature Genetics · doi:10.1038/ng.159 · Cited by 620 · cited 3×
“EZH2 is a key element of the Polycomb Repressive Complex 2 (PRC2) and is responsible for the establishment of the repressive H3K27 methylation mark [17,18].”
BackgroundInfluentialEzh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells
Ezhkova, E., Pasolli, H. A., Parker, J. S., Stokes, N., Su, I.-H., Hannon, G., Tarakhovsky, A., & Fuchs, E. (2009) · Cell · doi:10.1016/j.cell.2008.12.043 · Cited by 604 · cited 1×
“EZH2 is a key factor in the execution of development and differentiation programs as well as in maintenance of pluripotency and self-renewal of stem cells [38,39].”
BackgroundRepression of E-cadherin by the polycomb group protein EZH2 in cancer
Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H., Mani, R.-S., Tomlins, S. A., Mehra, R., Laxman, B., Cao, X., Yu, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.333 · Cited by 583
Polycomb group proteins: navigators of lineage pathways led astray in cancer
Bracken, A. P., & Helin, K. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2736 · Cited by 523
Wallace, T. A., Prueitt, R. L., Yi, M., Howe, T. M., Gillespie, J. W., Yfantis, H. G., Stephens, R. M., Caporaso, N. E., Loffredo, C. A., & Ambs, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2608 · Cited by 511 · cited 2×
“Microarray data from an independent study [14] were downloaded from the GEO public repository (GSE6956).”
MethodSilencing of human polycomb target genes is associated with methylation of histone H3 Lys 27
Kirmizis, A., Bartley, S. M., Kuzmichev, A., Margueron, R., Reinberg, D., Green, R., & Farnham, P. J. (2004) · Genes & Development · doi:10.1101/gad.1200204 · Cited by 495 · cited 1×
“). EZH2 is a histone H3 lysine 27 (H3K27) methyltransferase and a key element in epigenetic gene silencing”
BackgroundCooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
King, J. C., Xu, J., Wongvipat, J., Hieronymus, H., Carver, B. S., Leung, D. H., Taylor, B. S., Sander, C., Cardiff, R. D., Couto, S. S., et al. (2009) · Nature Genetics · doi:10.1038/ng.371 · Cited by 477 · cited 1×
“tion and cooperation with other oncogenic pathways, such as PTEN loss and PI3K/AKT dysregulation, is necessary [5,6,7,8,9].”
BackgroundETS transcription factors and their emerging roles in human cancer
Seth, A., & Watson, D. K. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.013 · Cited by 469 · cited 4×
“These findings are thus consistent with the ability of ETS factors to act alternatively as transcriptional activator and repressor [10,29] and with the hypothesis that transcription factors can influence the recruitment of epigenetic effectors like EZH2 to gene promoters [31].”
BackgroundInfluentialMYC stimulates EZH2 expression by repression of its negative regulator miR-26a
Sander, S., Bullinger, L., Klapproth, K., Fiedler, K., Kestler, H. A., Barth, T. F. E., Möller, P., Stilgenbauer, S., Pollack, J. R., & Wirth, T. (2008) · Blood · doi:10.1182/blood-2008-03-147645 · Cited by 395 · cited 2×
“EZH2 expression in prostate tumors [20,21,22,23].”
BackgroundFriedman, J. M., Liang, G., Liu, C.-C., Wolff, E. M., Tsai, Y. C., Ye, W., Zhou, X., & Jones, P. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3114 · Cited by 382 · cited 2×
“EZH2 expression in prostate tumors [20,21,22,23].”
BackgroundA Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome
Yu, J., Yu, J., Rhodes, D. R., Tomlins, S. A., Cao, X., Chen, G., Mehra, R., Wang, X., Ghosh, D., Shah, R. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2498 · Cited by 348 · cited 2×
“EZH2 is up-regulated in many cancers, including clinically localized and metastatic prostate cancers [19,37].”
BackgroundThe Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers
Tomlins, S. A., Rhodes, D. R., Yu, J., Varambally, S., Mehra, R., Perner, S., Demichelis, F., Helgeson, B. E., Laxman, B., Morris, D. S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.016 · Cited by 314 · cited 1×
“22Rv1 cells are ETStranslocation negative, AR-positive and androgen-independent [45].”
BackgroundA causal role for ERG in neoplastic transformation of prostate epithelium
Klezovitch, O., Risk, M., Coleman, I., Lucas, J. M., Null, M., True, L. D., Nelson, P. S., & Vasioukhin, V. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711711105 · Cited by 302 · cited 1×
“tion and cooperation with other oncogenic pathways, such as PTEN loss and PI3K/AKT dysregulation, is necessary [5,6,7,8,9].”
BackgroundEts proteins in biological control and cancer
Hsu, T., Trojanowska, M., & Watson, D. K. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20012 · Cited by 287 · cited 1×
“ETS factors have been reported to play an important role in extra-cellular matrix remodeling and epithelial-to-mesenchymal transition and their over-expression has been linked to increased motility, invasion and metastasis in various cancer models [35,36].”
BackgroundPathway Mapping Tools for Analysis of High Content Data
Ekins, S., Nikolsky, Y., Bugrim, A., Kirillov, E., & Nikolskaya, T. (2006) · High Content Screening · doi:10.1385/1-59745-217-3:319 · Cited by 255 · cited 1×
“To understand the functional implications of the differences among the tumor subgroups we used Metacore, a software suite for integrated functional analysis of the gene expression data [16].”
MethodIljin, K., Wolf, M., Edgren, H., Gupta, S., Kilpinen, S., Skotheim, R. I., Peltola, M., Smit, F., Verhaegh, G., Schalken, J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1986 · Cited by 241 · cited 1×
“This approach has been applied in previous studies [27,34].”
ResultZong, Y., Xin, L., Goldstein, A. S., Lawson, D. A., Teitell, M. A., & Witte, O. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905931106 · Cited by 203 · cited 1×
“tion and cooperation with other oncogenic pathways, such as PTEN loss and PI3K/AKT dysregulation, is necessary [5,6,7,8,9].”
BackgroundLei, Q., Jiao, J., Xin, L., Chang, C.-J., Wang, S., Gao, J., Gleave, M. E., Witte, O. N., Liu, X., & Wu, H. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.031 · Cited by 198 · cited 1×
“This transcription factor integrates multiple signaling pathways including PTEN/PI3K/AKT, p53 and AR, which all play critical roles in prostate development and tumorigenesis [25,42].”
BackgroundAndrogen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells
Berger, R., Febbo, P. G., Majumder, P. K., Zhao, J. J., Mukherjee, S., Signoretti, S., Campbell, K. T., Sellers, W. R., Roberts, T. M., Loda, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2938 · Cited by 177 · cited 2×
“ized LHS cells [32], which we have shown previously to express”
BackgroundMethodAbate-Shen, C. T., Shen, M. M., & Gelmann, E. P. (2008) · Differentiation · doi:10.1111/j.1432-0436.2008.00292.x · Cited by 175 · cited 5×
“1 acts as a prostate-specific tumor suppressor and its loss has an important role in tumor initiation and progression to invasive disease [25].”
BackgroundInfluentialDeletion, Methylation, and Expression of the NKX3.1 Suppressor Gene in Primary Human Prostate Cancer
Asatiani, E., Huang, W.-X., Wang, A., Rodriguez Ortner, E., Cavalli, L. R., Haddad, B. R., & Gelmann, E. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2688 · Cited by 156 · cited 2×
“1 in prostate cancers including allelic loss, methylation and post-transcriptional control [26,28].”
BackgroundPromoter‐specific transcriptional interference and c‐myc gene silencing by siRNAs in human cells
Napoli, S., Pastori, C., Magistri, M., Carbone, G. M., & Catapano, C. V. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.139 · Cited by 137 · cited 1×
“, were maintained in PrEC growth medium (PrEGM, Cambrex, Lonza Group Ltd, Basel, Switzerland). ERG expressing stable cell lines were generated by transfection of the pECFL-ha-ERG3 expressing vector (provided by S. Izraeli) using Lipofectamine 2000 (Invitrogen) and selection with G418. Negative control cells were obtai…”
MethodSelf-citationSong, H., Zhang, B., Watson, M. A., Humphrey, P. A., Lim, H. J., & Milbrandt, J. (2009) · Oncogene · doi:10.1038/onc.2009.181 · Cited by 123 · cited 1×
“1 has been associated with transformation and activation oncogenic pathways [44].”
BackgroundNext station in microarray data analysis: GEPAS
Montaner, D., Tarraga, J., Huerta-Cepas, J., Burguet, J., Vaquerizas, J. M., Conde, L., Minguez, P., Vera, J., Mukherjee, S., Valls, J., et al. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl197 · Cited by 119 · cited 3×
“To define the pathways affected in tumor subgroups the lists of differentially expressed genes obtained with GEPAS for each tumor subgroup compared to normal prostate were uploaded into the GeneGO’s Metacore server (http://portal.genego.com).”
MethodInfluentialGu, X., Zerbini, L. F., Otu, H. H., Bhasin, M., Yang, Q., Joseph, M. G., Grall, F. T., Onatunde, T., Correa, R. G., & Libermann, T. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3689 · Cited by 112
Cangemi, R., Mensah, A. A., Albertini, V., Jain, A., Grand, M. M., Chiorino, G., Catapano, C. V., & Carbone, G. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210953 · Cited by 81 · cited 10×
“RNA was reverse-transcribed and real-time PCR was performed using custom made primers and SYBR Green chemistry for ESE3 [11] and commercial primer sets for ERG, ESE1, ETS2, ETS1, ESE2 and PDEF (Applied Biosystems) on a ABI 7000 system.”
BackgroundMethodInfluentialSelf-citationSchedin, P. J., Eckel‐Mahan, K. L., McDaniel, S. M., Prescott, J. D., Brodsky, K. S., Tentler, J. J., & Gutierrez‐Hartmann, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207391 · Cited by 73 · cited 1×
“ESE1, which is closely related to ESE3, is expressed in normal epithelial cells of various organs, including prostate, breast and lung and is known to act as an oncogene when over-expressed in breast epithelial cells [12,13].”
BackgroundWu, J., Duan, R. C., Cao, H., Field, D. J., Newnham, C. M., Koehler, D. R., Zamel, N., Pritchard, M. A., Hertzog, P. J., Post, M., et al. (2008) · Cell Research · doi:10.1038/cr.2008.57 · Cited by 72 · cited 1×
“, inflammation) might be involved, since we showed that ESE3 is epigenetically silenced in prostate cancer cells [11] and both ESE3 and ESE1 expression can be affected by inflammatory stimuli [33].”
BackgroundMarkowski, M. C., Bowen, C., & Gelmann, E. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0578 · Cited by 72
Prescott, J. D., Koto, K., Singh, M., & Gutierrez‐Hartmann, A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5548-5564.2004 · Cited by 70 · cited 2×
“ESE1, which is closely related to ESE3, is expressed in normal epithelial cells of various organs, including prostate, breast and lung and is known to act as an oncogene when over-expressed in breast epithelial cells [12,13].”
BackgroundCarbone, G. M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg198 · Cited by 57 · cited 1×
“The region of the ETS2 promoter assessed by ChIP included the transcription start site and both RNA polymerase II and Sp1 had been shown to bind to this region in gel shift and ChIP assays ([24] and data not shown).”
BackgroundSelf-citationThe polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells
Bryant, R. J., Winder, S. J., Cross, S. S., Hamdy, F. C., & Cunliffe, V. T. (2007) · The Prostate · doi:10.1002/pros.20705 · Cited by 47 · cited 1×
“EZH2 has been shown to control also genes involved cell adhesion, invasion and migration [40,41], pathways that we found highly enriched in ERG and ESE3 tumors by functional annotation analysis.”
Gene expression profiles in the PC-3 human prostate cancer cells induced by NKX3.1
Zhang, P., Liú, W., Zhang, J., Guan, H., Chen, W., Cui, X., Liu, Q., & Jiang, A. (2009) · Molecular Biology Reports · doi:10.1007/s11033-009-9549-8 · Cited by 13 · cited 1×
“1 in PC3 cells, in which the gene is silenced, inhibited cell proliferation and invasion [43].”
Background
Cited by
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
“1, which is repressed via expression of ERG and is dependent on H3K27 trimethylation (Kunderfranco et al. 2010).”
BackgroundCell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
Mulholland, D. J., Tran, L. M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., Garraway, I. P., Huang, J., Graeber, T. G., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.006 · Cited by 516
“FKBP5 is an established androgen-regulated gene in humans (Magee et al., 2006; Mostaghel et al., 2007) whose expression is immediately suppressed after castration but upregulated upon hormone replacement in the WT mouse prostate (Figure S5B) and downregulated in the Pten null intact and castrated prostates (Figure S5C…”
BackgroundGenomic and biochemical insights into the specificity of ETS transcription factors
Hollenhorst, P. C., McIntosh, L. P., & Graves, B. J. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.79.081507.103945 · Cited by 490
Koh, C. M., Bieberich, C. J., Dang, C. V., Nelson, W. G., Yegnasubramanian, S., & De Marzo, A. M. (2010) · Genes & Cancer · doi:10.1177/1947601910379132 · Cited by 296
Regulation and Role of EZH2 in Cancer
Yamaguchi, H., & Hung, M.-C. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.3.209 · Cited by 287
“Moreover, NF-Y, STAT3, and ETS transcription factors directly regulate EZH2 transcription in epithelial ovarian, colorectal, and prostate cancer cells, respectively [14-16].”
Background
Metadata
- Authors
- Kunderfranco, P., Mello-Grand, M., Cangemi, R., Pellini, S., Mensah, A., Albertini, V., Malek, A., Chiorino, G., Catapano, C. V., & Carbone, G. M.
- Affiliations
- Istituto Oncologico della Svizzera Italiana (CH)
- Fondazione Edo ed Elvo Tempia (IT)
- Corresponding author
- Carbone, Giuseppina M.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-05-10
- Volume
- 5
- Issue
- 5
- Pages
- e10547
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2866657
- OpenAlex
- W1982538300
- Cited by
- 143
- References
- 49
- Citations by year
- 2025: 5 · 2024: 4 · 2023: 10 · 2022: 8 · 2021: 9 · 2020: 9 · 2019: 7 · 2018: 7 · 2017: 5 · 2016: 14 · 2015: 7 · 2014: 8 · 2013: 19 · 2012: 16
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Uni Genf
- Funders
- National Science Foundation
- Compagnia di San Paolo
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A, 118113)
- Oncosuisse
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- ETS transcription factors, prostate cancer, EZH2, NKX3.1, epigenetic silencing, ERG, Polycomb group proteins, tumor suppressor, prostate tumorigenesis, transcriptional regulation, tumor subtypes, gene expression signatures
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Transcriptional Regulator ERG, Aged, Cell Movement, DNA-Binding Proteins, Histones, Humans, Lysine, Male, Methylation, Middle Aged, Models, Genetic, Prostatic Neoplasms, Transcription Factors, Transcription, Genetic, Trans-Activators, Up-Regulation, Gene Expression Regulation, Neoplastic, Homeodomain Proteins, Gene Silencing, Gene Expression Profiling, Anoikis, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-ets, Gene Knockdown Techniques, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.